Cancer Chemical Biology and Metabolism Training Program

项目摘要/摘要 达纳-法伯癌症研究所(DFCI)的教职员工正在申请资金，以支持一项新的、综合性的、 癌症化学生物学和代谢(CCBM)博士后培训计划--两个协同和 概念上相关的以小分子化学和生物化学为基础的研究学科 从基础研究和翻译研究的角度来看，这一点日益重要。该计划的目标是： 1)提供与癌症化学生物学和新陈代谢相关的广泛主题的培训，如 临床前癌症靶点验证、化学筛选、基于结构的药物发现、肿瘤代谢 肿瘤和宿主代谢、细胞生物能量学和代谢组学之间的相互作用，机制 生物化学、蛋白质组学和化学蛋白质组学，以及动物肿瘤模型；2)使学员熟悉国家- 化学生物学和代谢科学方面的最新技术和方法，3)培训研究员以识别 将推动该领域向前发展并提供翻译机会的重要问题和方法 影响癌症治疗；4)为受训人员提供发展和提高他们的勇气的机会 和科学交流技能；5)通过以下方式指导研究员走向独立的科学职业生涯 实施个人发展计划(IDP)、个人博士后指导委员会和 为学员定制获得指导和教学经验的机会，具体取决于学员的 职业目标。 CCBM培训计划将每年支持8名博士后研究员进行为期2年的任命。会是 由一名主任(托马斯·罗伯茨博士，联系PD/PI)和一名联席主任(Nika Danial博士，PD/PI)管理， 并将包括来自DFCI 4个部门的26名导师和6名共同导师。项目总监和合作伙伴- 主任将与培训监督委员会(TOC)、外部咨询委员会(EAB)和 实习生领导的咨询小组，由现任和过去的计划研究员组成，他们将帮助确定 优化程序。衡量学员满意度、量化结果和评估的其他策略 该计划的有效性将包括来自学员和导师的年度调查，以及退出和 校友面试。还通过最先进的核心设施和技术平台提供机构支持 由于支持T32特定培训活动和每年的EAB会议的资金将显著提高 培训计划。除了在各种科学和职业发展方面提供强有力的培训外 技能，该计划的一个关键目标是招募和支持更多样化的受训人员群体。为进一步确保 该计划在增强多样性方面的有效性，我们的EAB和培训监督委员会包括领导人 在多样性和包容性方面有丰富的经验。我们相信CCBM综合培训计划将 使研究员为一系列的研究事业做好准备，并培训将在 21世纪的生物医学劳动力将在癌症研究和治疗方面取得突破。 好了！

Project Summary/Abstract The faculty of the Dana-Farber Cancer Institute (DFCI) is requesting funds to support a new, integrative, postdoctoral training program in Cancer Chemical Biology and Metabolism (CCBM) — two synergistic and conceptually related research disciplines grounded in small molecule chemistry and biochemistry that are of growing importance from both basic and translational research perspectives. The goals of this program are to: 1) provide training in a wide range of topics relevant to cancer chemical biology and metabolism such as preclinical cancer target validation, chemical screens, structure-based drug discovery, tumor metabolism, cross-talk between tumor and host metabolism, cellular bioenergetics and metabolomics, mechanistic biochemistry, proteomics and chemoproteomics, and animal tumor modelling; 2) familiarize trainees with state- of-the-art technologies and approaches in chemical biology and metabolic science, 3) train fellows to identify important questions and approaches that will move the field forward and provide translational opportunities to impact cancer treatment; 4) provide trainees with opportunities to develop and enhance their grantsmanship and scientific communication skills; 5) coach fellows on their paths to independent careers in science by implementing Individual Development Plans (IDPs), individual postdoctoral mentoring committees, and customized opportunities for trainees to acquire experience in mentoring and teaching depending on their career goals. The CCBM Training Program will support 8 postdoctoral fellows per year for 2-year appointments. It will be administered by a Director (Dr. Thomas Roberts, Contact PD/PI) and a co-Director (Dr. Nika Danial, PD/PI), and will include 26 mentors and 6 co-mentors from 4 departments at DFCI. The program Director and co- Director will work closely with a Training Oversight Committee (TOC), an External Advisory Board (EAB), and a trainee-led advisory group consisting of current and past program fellows who will help identify ways to optimize the program. Additional strategies to measure trainee satisfaction, quantify outcomes, and evaluate the effectiveness of the program will include annual surveys from trainees and mentors, as well as exit and alumni interviews. Institutional support through state-of-the-art core facilities and technology platforms, as well as funds to support T32-specific training activities and yearly EAB meetings will significantly enhance the training program. In addition to offering robust training in a diverse range of scientific and career development skills, a key goal of the program is to recruit and support a more diverse group of trainees. To further ensure the program's effectiveness in enhancing diversity, our EAB and Training Oversight Committee include leaders with deep experience in diversity and inclusion. We believe the integrative CCBM Training Program will prepare fellows for a range of research careers and train the next generation of scientists who will thrive in the 21st century biomedical workforce that will make breakthroughs in cancer research and treatment. !